Karen M King is Former Global Head:Investor Relations at Sandoz Group AG. See Karen M King's compensation, career history, education, & memberships.

Oct 4, 2023 · Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. 22,000 people of more than...

Karen King is currently Head, Global Investor Relations at Sandoz Switzerland - View - Sandoz Switzerland org chart. Create your alert to follow the career of Karen King.

Nov 10, 2023 · Investment of EUR 175 million reaffirms Sandoz commitment to long-term leadership in off-patent medicines; New penicillin production process will significantly improve ecological footprint and help secure European-based supply; Cutting-edge development hub will play key role in supporting long-term growth of leading biosimilar business

Basel, March 5, 2024 - The Board of Directors of Sandoz announced today that it proposes Mathai Mammen, M.D., Ph.D., and Michael Rechsteiner for election to its Board of Directors at the...

Karen King General Information Biography. Mr. Karen King serves as Head, Global Investor Relations at Sandoz Group.

Basel, February 1, 2024 – The Board of Directors of Sandoz announced today that it proposes Graeme Pitkethly for election to its Board of Directors at the company’s next Annual General Meeting on April 30, 2024.

I recently joined the Sandoz team and couldn't be prouder today to be part of the bell ringing ceremony as the company recognized its independence as a new standalone company.

I will now pass on to Karen King, Global Head of Investor Relations, for her opening remarks. Welcome to Sandoz's half year results 2024. Earlier today, we issued our half year 2024 report, including the financial statements of the company for the first half of the year.